Diabetes as a risk factor for tuberculosis disease.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
epublish
Résumé
Tuberculosis (TB) is amongst the leading causes of death from an infectious disease, with an estimated 1.3 million deaths from TB in 2022. Approximately 25% of the global population is estimated to be infected with the TB bacterium, giving rise to 10.6 million episodes of TB disease in 2022. The prevalence of diabetes influences TB incidence and TB mortality. It is associated not only with an increased risk of TB disease but also death during TB treatment, TB relapse after treatment completion and multidrug-resistant TB. Since 2011, the World Health Organization (WHO) has recommended collaborative TB and diabetes activities as outlined in the Collaborative Framework for Care and Control of TB and Diabetes. To determine the prognostic value of diabetes mellitus (DM) in the general population of adults, adolescents and children for predicting tuberculosis disease. We searched the literature databases MEDLINE (via PubMed) and WHO Global Index Medicus, and the WHO International Clinical Trials Registry Platform (ICTRP) on 3 May 2023 (date of last search for all databases); we placed no restrictions on the language of publication. We included retrospective and prospective cohort studies, irrespective of publication status or language. The target population comprised adults, adolescents and children from diverse settings, encompassing outpatient and inpatient cohorts, with varying comorbidities and risk of exposure to tuberculosis. We used standard Cochrane methodology and the Quality In Prognosis Studies (QUIPS) tool. Prognostic factors assessed at enrolment/baseline included diabetes, as defined by the individual studies, encompassing patient-reported status, abstracted from medical records or claims data, or diagnosed by plasma glucose/glycosylated haemoglobin. The primary outcome was the incidence of tuberculosis disease. The secondary outcome was recurrent TB disease. We performed a random-effects meta-analysis for the adjusted hazard ratios, risk ratios, or odds ratios, employing the restricted maximum likelihood estimation. We rated the certainty of the evidence using the GRADE approach. We included 48 cohort studies with over 61 million participants from the six WHO regions. However, the representation was variable as eight population-based studies were from South Korea and 19 from China, with overlapping study periods, and only one from the African region (Ethiopia). All studies included adults, and nine studies also included children and adolescents. Most studies diagnosed DM based on clinical records, including fasting blood glucose levels or glucose-lowering treatments. The studies did not distinguish between type 1 and type 2 DM; only one study focused on type 1 DM. Diagnosis and exclusion of TB were performed using culture or molecular WHO-recommended rapid diagnostic tests (mWRD) in only 12 studies, which could have biassed the effect estimate. The median follow-up time was five years (interquartile range 1.5 to 10, range 1 to 16.9), and the studies primarily reported an adjusted hazard ratio from a multivariable Cox-proportional hazard model. Hazard Ratios (HR) The HR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. We present 95% confidence intervals (CI) and prediction intervals, which show between-study heterogeneity represented in measuring the variability of effect sizes (i.e. the interval within which the effect size of a new study would fall considering the same population of studies included in the meta-analysis). DM may increase the risk of tuberculosis disease (HR 1.90, 95% CI 1.51 to 2.40; prediction interval 0.83 to 4.39; 10 studies; 11,713,023 participants). The certainty of the evidence is low, due to a moderate risk of bias across studies and inconsistency. Considering a risk without diabetes of 129 cases per 100,000 population, this represents 102 more (59 to 153 more) cases per 100,000. When stratified by follow-up time, the results are more consistent across < 10 years follow-up (HR 1.52, 95% CI 1.47 to 1.57; prediction interval 1.45 to 1.59; 7 studies; 10,380,872 participants). This results in a moderate certainty of the evidence due to a moderate risk of bias across studies. However, at 10 or more years of follow-up, the estimates yield a wider CI and a higher HR (HR 2.44, 95% CI 1.22 to 4.88; prediction interval 0.09 to 69.12; 3 studies; 1,332,151 participants). The certainty of the evidence is low due to the moderate risk of bias and inconsistency. Odds Ratio (OR) DM may increase the odds of tuberculosis disease (OR 1.61, 95% CI 1.27 to 2.04; prediction interval 0.96 to 2.70; 4 studies; 167,564 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is low due to a moderate risk of bias and inconsistency. Risk Ratio (RR) The HR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. DM probably increases the risk of tuberculosis disease (RR 1.60, 95% CI 1.42 to 1.80; prediction interval 1.38 to 1.85; 6 studies; 44,058,675 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is moderate due to a moderate risk of bias. Diabetes probably increases the risk of developing TB disease in the short term (< 10 years) and may also increase the risk in the long term (≥ 10 years). As glycaemic control and access to care may be potential effect modifiers of the association between diabetes and the risk of TB disease, the overall estimates should be interpreted with caution when applied locally. Policies targeted at reducing the burden of diabetes are needed to contribute to the aims of ending TB. Large population-based cohorts, including those derived from high-quality national registries of exposures (diabetes) and outcomes (TB disease), are needed to provide estimates with a high certainty of evidence of this risk across different settings and populations, including low- and middle-income countries from different WHO regions. Moreover, studies including children and adolescents and currently recommended methods for diagnosing TB would provide more up-to-date information relevant to practice and policy. World Health Organization (203256442) REGISTRATION: PROSPERO registration: CRD42023408807.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis (TB) is amongst the leading causes of death from an infectious disease, with an estimated 1.3 million deaths from TB in 2022. Approximately 25% of the global population is estimated to be infected with the TB bacterium, giving rise to 10.6 million episodes of TB disease in 2022. The prevalence of diabetes influences TB incidence and TB mortality. It is associated not only with an increased risk of TB disease but also death during TB treatment, TB relapse after treatment completion and multidrug-resistant TB. Since 2011, the World Health Organization (WHO) has recommended collaborative TB and diabetes activities as outlined in the Collaborative Framework for Care and Control of TB and Diabetes.
OBJECTIVES
OBJECTIVE
To determine the prognostic value of diabetes mellitus (DM) in the general population of adults, adolescents and children for predicting tuberculosis disease.
SEARCH METHODS
METHODS
We searched the literature databases MEDLINE (via PubMed) and WHO Global Index Medicus, and the WHO International Clinical Trials Registry Platform (ICTRP) on 3 May 2023 (date of last search for all databases); we placed no restrictions on the language of publication.
SELECTION CRITERIA
METHODS
We included retrospective and prospective cohort studies, irrespective of publication status or language. The target population comprised adults, adolescents and children from diverse settings, encompassing outpatient and inpatient cohorts, with varying comorbidities and risk of exposure to tuberculosis.
DATA COLLECTION AND ANALYSIS
METHODS
We used standard Cochrane methodology and the Quality In Prognosis Studies (QUIPS) tool. Prognostic factors assessed at enrolment/baseline included diabetes, as defined by the individual studies, encompassing patient-reported status, abstracted from medical records or claims data, or diagnosed by plasma glucose/glycosylated haemoglobin. The primary outcome was the incidence of tuberculosis disease. The secondary outcome was recurrent TB disease. We performed a random-effects meta-analysis for the adjusted hazard ratios, risk ratios, or odds ratios, employing the restricted maximum likelihood estimation. We rated the certainty of the evidence using the GRADE approach.
MAIN RESULTS
RESULTS
We included 48 cohort studies with over 61 million participants from the six WHO regions. However, the representation was variable as eight population-based studies were from South Korea and 19 from China, with overlapping study periods, and only one from the African region (Ethiopia). All studies included adults, and nine studies also included children and adolescents. Most studies diagnosed DM based on clinical records, including fasting blood glucose levels or glucose-lowering treatments. The studies did not distinguish between type 1 and type 2 DM; only one study focused on type 1 DM. Diagnosis and exclusion of TB were performed using culture or molecular WHO-recommended rapid diagnostic tests (mWRD) in only 12 studies, which could have biassed the effect estimate. The median follow-up time was five years (interquartile range 1.5 to 10, range 1 to 16.9), and the studies primarily reported an adjusted hazard ratio from a multivariable Cox-proportional hazard model. Hazard Ratios (HR) The HR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. We present 95% confidence intervals (CI) and prediction intervals, which show between-study heterogeneity represented in measuring the variability of effect sizes (i.e. the interval within which the effect size of a new study would fall considering the same population of studies included in the meta-analysis). DM may increase the risk of tuberculosis disease (HR 1.90, 95% CI 1.51 to 2.40; prediction interval 0.83 to 4.39; 10 studies; 11,713,023 participants). The certainty of the evidence is low, due to a moderate risk of bias across studies and inconsistency. Considering a risk without diabetes of 129 cases per 100,000 population, this represents 102 more (59 to 153 more) cases per 100,000. When stratified by follow-up time, the results are more consistent across < 10 years follow-up (HR 1.52, 95% CI 1.47 to 1.57; prediction interval 1.45 to 1.59; 7 studies; 10,380,872 participants). This results in a moderate certainty of the evidence due to a moderate risk of bias across studies. However, at 10 or more years of follow-up, the estimates yield a wider CI and a higher HR (HR 2.44, 95% CI 1.22 to 4.88; prediction interval 0.09 to 69.12; 3 studies; 1,332,151 participants). The certainty of the evidence is low due to the moderate risk of bias and inconsistency. Odds Ratio (OR) DM may increase the odds of tuberculosis disease (OR 1.61, 95% CI 1.27 to 2.04; prediction interval 0.96 to 2.70; 4 studies; 167,564 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is low due to a moderate risk of bias and inconsistency. Risk Ratio (RR) The HR estimates represent the highest certainty of the evidence, explored through sensitivity analyses and excluding studies at high risk of bias. DM probably increases the risk of tuberculosis disease (RR 1.60, 95% CI 1.42 to 1.80; prediction interval 1.38 to 1.85; 6 studies; 44,058,675 participants). Stratification by follow-up time was not possible as all studies had a follow-up < 10 years. The certainty of the evidence is moderate due to a moderate risk of bias.
AUTHORS' CONCLUSIONS
CONCLUSIONS
Diabetes probably increases the risk of developing TB disease in the short term (< 10 years) and may also increase the risk in the long term (≥ 10 years). As glycaemic control and access to care may be potential effect modifiers of the association between diabetes and the risk of TB disease, the overall estimates should be interpreted with caution when applied locally. Policies targeted at reducing the burden of diabetes are needed to contribute to the aims of ending TB. Large population-based cohorts, including those derived from high-quality national registries of exposures (diabetes) and outcomes (TB disease), are needed to provide estimates with a high certainty of evidence of this risk across different settings and populations, including low- and middle-income countries from different WHO regions. Moreover, studies including children and adolescents and currently recommended methods for diagnosing TB would provide more up-to-date information relevant to practice and policy.
FUNDING
BACKGROUND
World Health Organization (203256442) REGISTRATION: PROSPERO registration: CRD42023408807.
Identifiants
pubmed: 39177079
doi: 10.1002/14651858.CD016013.pub2
doi:
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD016013Informations de copyright
Copyright © 2024 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.
Références
World Health Organization. Global Tuberculosis Report 2023. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (accessed 12 April 2024).
CDC. Core Curriculum on Tuberculosis: What the clinician should know. https://www.cdc.gov/tb/education/corecurr/index.htm (accessed 21 April 2023).
Brett K, Dulong C, Severn M; Canadian Agency for Drugs and Technologies in Health. Prevention of Tuberculosis: A Review of Guidelines 2020. pubmed.ncbi.nlm.nih.gov/33048484/ (accessed prior to 3 August 2024). [PMID: 33048484]
pubmed: 33048484
Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JD. The social determinants of tuberculosis: from evidence to action. American Journal of Public Health 2011;101(4):654-62. [DOI: 10.2105/AJPH.2010.199505]
World Health Organization. Tuberculosis and vulnerable populations. https://www.who.int/europe/news-room/fact-sheets/item/tuberculosis-and-vulnerable-populations (accessed 7 July 2023).
American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes - 2022. Diabetes Care 2022;45(Suppl 1):S17-S38. [DOI: 10.2337/dc22-S002]
Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, et al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia 2021;64(12):2741-50. [DOI: 10.1007/s00125-021-05571-8]
International Diabetes Federation. IDF Diabetes Atlas. https://www.diabetesatlas.org (accessed 21 April 2023)(10th edition).
Menzies NA, Swartwood N, Testa C. Time since infection and risks of future disease for individuals with Mycobacterium tuberculosis infection in the United States. Epidemiology 2021;1:70-8. [DOI: 10.1097/EDE.0000000000001271]
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E. Official American Thoracic Society/infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clinical Infectious Diseases 2017;64(2):111-5. [DOI: 10.1093/cid/ciw778]
World Health Organization (editors). WHO Operational Handbook on Tuberculosis: Module 3: Diagnosis: Rapid diagnostics for tuberculosis detection, 2021 update. https://www.who.int/publications/i/item/9789240030589 (accessed 26 April 2024).
World Health Organization (editors). WHO Consolidated Guidelines on Tuberculosis: Module 5: Management of tuberculosis in children and adolescents. https://www.who.int/publications/i/item/9789240046764 (accessed 26 April 2024).
Vega V, Rodríguez S, Van der Stuyft P, Seas C, Otero L. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax 2021;76:494-502.
WHO. WHO Consolidated Guidelines on Tuberculosis: Module 2: Screening: systematic screening for tuberculosis disease. https://www.who.int/publications/i/item/9789240022676 (accessed 01 July 2024).
Hayashi S, Chandramohan D. Risk of active tuberculosis among people with diabetes mellitus: systematic review and meta-analysis. Tropical Medicine & International Health 2018;23(10):1058-70. [PMID: 30062731]
pubmed: 30062731
Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. European Respiratory Journal 2017;50(1):1700216. [PMID: 28705945]
pubmed: 28705945
Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. International Journal of Epidemiology 2010;39(1):149-55. [PMID: 19820104]
pubmed: 19820104
Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:9728. [DOI: 10.1016/S0140-6736(10)60483-7]
Franco JV, Bongaerts B, Metzendorf MI, Risso A, Guo Y, Peña Silva L, et al. Undernutrition as a risk factor for tuberculosis disease. Cochrane Database of Systematic Reviews 2024, Issue 6. Art. No: CD015890. [DOI: 10.1002/14651858.CD015890.pub2]
Higgins JP, Lasserson T, Thomas J, Flemyng E, Churchill R. Methodological Expectations of Cochrane Intervention Reviews. London: Cochrane, August 2023.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research Ed.) 2021;372:n71. [DOI: 10.1136/bmj.n71]
Franco JV, Metzendorf M-I, Risso A, Boeckmann M, Schlesinger S, Damen JAAG, et al. Diabetes as a risk factor for tuberculosis disease. Cochrane Database of Systematic Reviews 2023, Issue 10. Art. No: CD016013. [DOI: 10.1002/14651858.CD016013]
Garegnani L, Franco JV, Melendi SE, Vernooij RW, Jung JH, Hwang EC. Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay. Cochrane Database of Systematic Reviews 2023, Issue 3. Art. No: CD014746. [DOI: 10.1002/14651858.CD014746]
Perais J, Agarwal R, Evans JR, Loveman E, Colquitt JL, Owens D. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. Cochrane Database of Systematic Reviews 2023, Issue 2. Art. No: CD013775. [DOI: 10.1002/14651858.CD013775.pub2]
World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). https://apps.who.int/iris/bitstream/handle/10665/331710/WHO-UCN-NCD-20.1-eng.pdf (accessed 13 January 2023)(7th edition).
Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PloS One 2017;12(11):e0187967. [PMID: 29161276]
pubmed: 29161276
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 2008;5(7):e152. [PMID: 18630984]
pubmed: 18630984
Obels I, Ninsiima S, Critchley JA, Huangfu P. Tuberculosis risk among people with diabetes mellitus in Sub-Saharan Africa: a systematic review. Tropical Medicine & International Health 2022;27(4):369-86. [PMID: 35146851]
pubmed: 35146851
Adam GP, Paynter R. Development of literature search strategies for evidence syntheses: pros and cons of incorporating text mining tools and objective approaches. BMJ Evidence-Based Medicine 2023;28:137-9.
Covidence. Version (accessed 18 September 2023). Melbourne, Australia: Veritas Health Innovation, 2023. Available at covidence.org.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Moons KG, De Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Medicine 2014;11(10):e1001744. [DOI: 10.1371/journal.pmed.1001744]
Riley RD, Moons KG, Snell KI, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ (Clinical Research Ed.) 2019;364:k4597. [DOI: 10.1136/bmj.k4597]
Hayden JA, Van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of Internal Medicine 2013;158(4):280-6.
Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ (Clinical Research Ed.) 2003;326(7382):219. [DOI: 10.1136/bmj.326.7382.219]
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PMID: 9921604]
pubmed: 9921604
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [DOI: 10.1186/1745-6215-8-16]
Peat G, Riley RD, Croft P, Morley KI, Kyzas PA, Moons KG. Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. PLoS Medicine 2014;11(7):e1001671. [DOI: 10.1371/journal.pmed.1001671]
Stata 18. College Station, TX, USA: StataCorp LLC, 2023. available from https://www.stata.com.
Debray TP, Moons KG, Riley RD. Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: a comparison of new and existing tests. Research Synthesis Methods 2018;9(1):41-50.
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ (Clinical Research Ed.) 2011;342:d549. [DOI: 10.1136/bmj.d549]
McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.
Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. Journal of Clinical Epidemiology 2020;121:62-70. [PMID: 31982539]
pubmed: 31982539
Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ (Clinical Research Ed.) 2015;350:h870. [DOI: 10.1136/bmj.h870]
Agarwal SK, Bhowmik D, Mahajan S, Bagchi S. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: single-center study from India. Transplant Infectious Disease 2017;19(1):e12626. [DOI: 10.1111/tid.12626]
Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992. American Journal of Epidemiology 2012;176(5):409-22. [DOI: 10.1093/aje/kws007]
Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clinical Infectious Diseases 2013;56(6):770-6. [DOI: 10.1093/cid/cis1008]
Hu HY, Wu CY, Huang N, Chou YJ, Chang YC, Chu D. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiology and Infection 2014;142(1):191-9. [DOI: 10.1017/s0950268813000551]
John GT, Shankar V, Abraham AM, Mukundan U, Thomas PP, Jacob CK. Risk factors for post-transplant tuberculosis. Kidney International 2001;60(3):1148-53. [DOI: 10.1046/j.1523-1755.2001.0600031148.x]
Lee CH, Lee MC, Shu CC, Lim CS, Wang JY, Lee LN, et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infectious Diseases 2013;13:194. [DOI: 10.1186/1471-2334-13-194]
Morán-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. International Journal of Tuberculosis and Lung Disease 2010;14(9):1112-9.
Pealing L, Wing K, Mathur R, Prieto-Merino D, Smeeth L, Moore DA. Risk of tuberculosis in patients with diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMC Medicine 2015;13:135. [DOI: 10.1186/s12916-015-0381-9]
Soh AZ, Chee CB, Wang YT, Yuan JM, Koh WP. Diabetes and body mass index in relation to risk of active tuberculosis: a prospective population-based cohort. International Journal of Tuberculosis and Lung Disease 2019;23(12):1277-82. [DOI: 10.5588/ijtld.19.0094]
Wu PH, Lin YT, Yang YH, Lin YC. The increased risk of active tuberculosis disease in patients with dermatomyositis - a nationwide retrospective cohort study. Scientific Reports 2015;5:16303. [DOI: 10.1038/srep16303]
Young F, Wotton CJ, Critchley JA, Unwin NC, Goldacre MJ. Increased risk of tuberculosis disease in people with diabetes mellitus: record-linkage study in a UK population. Journal of Epidemiology and Community Health 2012;66(6):519-23. [DOI: 10.1136/jech.2010.114595]
Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, et al. Nutritional status and tuberculosis risk in adult and pediatric household contacts. PloS One 2016;11(11):e0166333. [DOI: 10.1371/journal.pone.0166333]
Anaam MS, Alrasheedy AA, Alsahali S, Alfadly SO, Aldhubhani AH. Rate and risk factors of recurrent tuberculosis in Yemen: a 5-year prospective study. Infectious Diseases (London, England) 2020;52(3):161-9. [DOI: 10.1080/23744235.2019.1690162]
Antonio-Arques V, Franch-Nadal J, Moreno-Martinez A, Real J, Orcau À, Mauricio D, et al. Subjects with diabetes mellitus are at increased risk for developing tuberculosis: a cohort study in an inner-city district of barcelona (Spain). Frontiers in Public Health 2022;10:789952. [DOI: 10.3389/fpubh.2022.789952]
Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clinical Infectious Diseases 2012;54(6):818-25. [DOI: 10.1093/cid/cir939]
Byberg S, Soborg B, Andersson M, Bjerregaard P, Jørgensen ME. Diabetes is a risk factor for tuberculosis in the Inuit population of Greenland. European Respiratory Journal 2012;40(5):1289-91. [DOI: 10.1183/09031936.00039612]
Chen W, Shu W, Wang M, Hou Y, Xia Y, Xu W, et al. Pulmonary tuberculosis incidence and risk factors in rural areas of China: a cohort study. PloS One 2013;8(3):e58171. [DOI: 10.1371/journal.pone.0058171]
Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: a cohort study in Taiwan. Medicine 2018;97(39):e12550. [DOI: 10.1097/md.0000000000012550]
Choi H, Yoo JE, Han K, Choi W, Rhee SY, Lee H, et al. Body mass index, diabetes, and risk of tuberculosis: a retrospective cohort study. Frontiers in Nutrition 2021;8:739766. [DOI: 10.3389/fnut.2021.739766]
Chu KA, Hsu CH, Lin MC, Chu YH, Hung YM, Wei JC. Association of iron deficiency anemia with tuberculosis in Taiwan: a nationwide population-based study. PloS One 2019;14(8):e0221908. [DOI: 10.1371/journal.pone.0221908]
Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2012;2(1):e000666. [DOI: 10.1136/bmjopen-2011-000666]
Fang WL, Hung YP, Liu CJ, Lan YT, Huang KH, Chen MH, et al. Incidence of and risk factors for tuberculosis (TB) in gastric cancer patients in an area endemic for TB: a nationwide population-based matched cohort study. Medicine 2015;94(47):e2163. [DOI: 10.1097/md.0000000000002163]
Golub JE, Mok Y, Hong S, Jung KJ, Jee SH, Samet JM. Diabetes mellitus and tuberculosis in Korean adults: impact on tuberculosis incidence, recurrence and mortality. International Journal of Tuberculosis and Lung Disease 2019;23(4):507-13. [DOI: 10.5588/ijtld.18.0103]
Hsien FL, Kuan FL, Ching MC, Shih WL, Pang YT, Fung CS. Anti-diabetic medication reduces risk of pulmonary tuberculosis in diabetic patients: a population-based cohort study in Taiwan. Kuwait Medical Journal 2017;49:22-8.
Ko TH, Chang YC, Chang CH, Liao KC, Magee MJ, Lin HH. Prediabetes and risk of active tuberculosis: a cohort study from Northern Taiwan. International Journal of Epidemiology 2022;52(3):932-41. [DOI: 10.1093/ije/dyac214]
Kuo MC, Lin SH, Lin CH, Mao IC, Chang SJ, Hsieh MC. Type 2 diabetes: an independent risk factor for tuberculosis: a nationwide population-based study. PloS One 2013;8(11):e78924. [DOI: 10.1371/journal.pone.0078924]
Lee MS, Leung CC, Kam KM, Wong MY, Leung MC, Tam CM, et al. Early and late tuberculosis risks among close contacts in Hong Kong. International Journal of Tuberculosis and Lung Disease 2008;12(3):281-7.
Lee PH, Fu H, Lai TC, Chiang CY, Chan CC, Lin HH. Glycemic control and the risk of tuberculosis: a cohort study. PLoS Medicine 2016;13(8):e1002072. [DOI: 10.1371/journal.pmed.1002072]
Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung GM, et al. Diabetic control and risk of tuberculosis: a cohort study. American Journal of Epidemiology 2008;167(12):1486-94. [DOI: 10.1093/aje/kwn075]
Li CH, Chen HJ, Chen WC, Tu CY, Hsia TC, Hsu WH, et al. The risk of tuberculosis infection in non-dialysis chronic kidney disease patients. Frontiers in Medicine 2021;8:715010. [DOI: 10.3389/fmed.2021.715010]
Liao TL, Lin CH, Chen YM, Chang CL, Chen HH, Chen DY. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PloS One 2016;11(4):e0153217. [DOI: 10.1371/journal.pone.0153217]
Lin HH, Wu CY, Wang CH, Fu H, Lönnroth K, Chang YC, et al. Association of obesity, diabetes, and risk of tuberculosis: two population-based cohorts. Clinical Infectious Diseases 2018;66(5):699-705. [DOI: 10.1093/cid/cix852]
Lo HY, Yang SL, Lin HH, Bai KJ, Lee JJ, Lee TI, et al. Does enhanced diabetes management reduce the risk and improve the outcome of tuberculosis? International Journal of Tuberculosis and Lung Disease 2016;20(3):376-82. [DOI: 10.5588/ijtld.15.0654]
Mor A, Berencsi K, Nielsen JS, Rungby J, Friborg S, Brandslund I, et al. Rates of community-based antibiotic prescriptions and hospital-treated infections in individuals with and without type 2 diabetes: a Danish nationwide cohort study, 2004-2012. Clinical Infectious Diseases 2016;63(4):501-11. [DOI: 10.1093/cid/ciw345]
Park HY, Choi SH, Kim D, Hwang J, Kwon Y, Kwon JW. Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data. Gastric Cancer 2023;26(3):405-14. [DOI: 10.1007/s10120-023-01367-4]
Pearson F, Huangfu P, McNally R, Pearce M, Unwin N, Critchley JA. Tuberculosis and diabetes: bidirectional association in a UK primary care data set. Journal of Epidemiology and Community Health 2019;73(2):142-7. [DOI: 10.1136/jech-2018-211231]
Rajan JV, Ferrazoli L, Waldman EA, Simonsen V, Ferreira P, Telles MA, et al. Diabetes increases the risk of recent-transmission tuberculosis in household contacts in São Paulo, Brazil. International Journal of Tuberculosis and Lung Disease 2017;21(8):916-21. [DOI: 10.5588/ijtld.16.0043]
Shen TC, Lin CL, Wei CC, Liao WC, Chen WC, Chen CH, et al. Increased risk of tuberculosis in patients with type 1 diabetes mellitus: results from a population-based cohort study in Taiwan. Medicine 2014;93(16):e96. [DOI: 10.1097/md.0000000000000096]
Teng CJ, Huon LK, Zheng YM, Yeh CM, Tsai CK, Liu JH, et al. Increased risk of tuberculosis in oral cancer patients in an endemic area: a nationwide population-based study. Clinical Oral Investigations 2019;23(12):4223-31. [DOI: 10.1007/s00784-019-02864-6]
Tipayamongkholgul M, Marin W, Sujirarat D, Pokaew P, Pungrassami P. Non-communicable diseases increased risk of recurrent tuberculosis in epidemic area of Human Immunodeficiency Virus infection, Thailand. Tropical Biomedicine 2016;33(1):190-6.
Yen YF, Hu HY, Lee YL, Ku PW, Lin IF, Chu D, et al. Obesity/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan. International Journal of Obesity (2005) 2017;41(6):971-5. [DOI: 10.1038/ijo.2017.64]
Yoo JE, Kim D, Choi H, Kang YA, Han K, Lee H, et al. Anemia, sarcopenia, physical activity, and the risk of tuberculosis in the older population: a nationwide cohort study. Therapeutic Advances in Chronic Disease 2021;12:20406223211015959. [DOI: 10.1177/20406223211015959]
Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes status and association with risk of tuberculosis among Korean adults. JAMA Network Open 2021;4(9):e2126099. [DOI: 10.1001/jamanetworkopen.2021.26099]
Youn HM, Shin MK, Jeong D, Kim HJ, Choi H, Kang YA. Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study. PloS One 2022;17(6):e0268290. [DOI: 10.1371/journal.pone.0268290]
Eksombatchai D, Jeong D, Mok J, Jeon D, Kang HY, Kim HJ, et al. Sex differences in the impact of diabetes mellitus on tuberculosis recurrence: a retrospective national cohort study. International Journal of Infectious Diseases 2023;127:1-10. [DOI: 10.1016/j.ijid.2022.11.037]
Gedfew M. Predictors of extrapulmonary tuberculosis among diabetic patients at Debre Markos compressive specialized hospital, Ethiopia, 2021: a retrospective cohort study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2021;25:100280. [DOI: 10.1016/j.jctube.2021.100280]
Gedfew M, Ayana M, Abate A, Bewket B, Haile D, Edmealem A, et al. Incidence and predictors of tuberculosis among adult diabetic patients, Debre Markos referral hospital, northwest Ethiopia, 2018: a retrospective cohort study. Diabetes, Metabolic Syndrome and Obesity 2020;13:869-78. [DOI: 10.2147/dmso.S233564]
Lu P, Zhang Y, Liu Q, Ding X, Kong W, Zhu L, et al. Association of BMI, diabetes, and risk of tuberculosis: a population-based prospective cohort. International Journal of Infectious Diseases 2021;109:168-73. [DOI: 10.1016/j.ijid.2021.06.053]
Park S, Lee S, Kim Y, Lee Y, Kang MW, Cho S, et al. Association of CKD with incident tuberculosis. Clinical Journal of the American Society of Nephrology 2019;14(7):1002-10. [DOI: 10.2215/cjn.14471218]
WHO. Global report on diabetes. https://www.who.int/publications/i/item/9789241565257 (accessed 26 April 2024).
Balooch Hasankhani M, Mirzaei H, Karamoozian A. Global trend analysis of diabetes mellitus incidence, mortality, and mortality-to-incidence ratio from 1990 to 2019. Scientific Reports 2023;13(1):21908. [DOI: 10.1038/s41598-023-49249-0]
IDF Diabetes Atlas. Diabetes foot-related complications. https://diabetesatlas.org/idfawp/resource-files/2022/12/IDF-Diabetic-Foot-Report.pdf (accessed 12 April 2024).
Venkatraman S, Echouffo-Tcheugui JB, Selvin E, Fang M. Trends and disparities in glycemic control and severe hyperglycemia among US adults with diabetes using insulin, 1988-2020. JAMA Network Open 2022;5(12):e2247656. [PMID: 10.1001/jamanetworkopen.2022.47656]
pubmed: 10.1001/jamanetworkopen.2022.47656
Chávez-Reyes J, Escárcega-González CE, Chavira-Suárez E, León-Buitimea A, Vázquez-León P, Morones-Ramírez JR, et al. Susceptibility for some infectious diseases in patients with diabetes: the key role of glycemia. Frontiers Public Health 2021;9:559595. [DOI: 10.3389/fpubh.2021.559595]
Foe-Essomba JR, Kenmoe S, Tchatchouang S, Ebogo-Belobo JT, Mbaga DS, Kengne-Ndé C, et al. Diabetes mellitus and tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders. PloS One 2021;16(12):e0261246. [DOI: 10.1371/journal.pone.0261246]